Spyre Therapeutics Inc. (SYRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spyre Therapeutics Inc. (SYRE) has a cash flow conversion efficiency ratio of -0.082x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.12 Million) by net assets ($455.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Spyre Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Spyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Spyre Therapeutics Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Spyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spyre Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tongding Interconnection Information
SHE:002491
|
-0.002x |
|
MNC Studios International Tbk PT
JK:MSIN
|
0.029x |
|
Synaptics Incorporated
NASDAQ:SYNA
|
0.022x |
|
Digitalbridge Group Inc
NYSE:DBRG
|
0.031x |
|
AIR FRANCE-KLM ADR EO 85
F:FQZ
|
N/A |
|
China Suntien Green Energy Corp Ltd
SHG:600956
|
0.093x |
|
HSBC Holdings PLC
LSE:HSBA
|
0.002x |
|
Jiangsu Broadcasting Cable inf
SHG:600959
|
0.005x |
Annual Cash Flow Conversion Efficiency for Spyre Therapeutics Inc. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Spyre Therapeutics Inc. from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Spyre Therapeutics Inc. (SYRE) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $517.80 Million | $-157.41 Million | -0.304x | +44.01% |
| 2023-12-31 | $184.02 Million | $-99.91 Million | -0.543x | +65.92% |
| 2022-12-31 | $50.30 Million | $-80.14 Million | -1.593x | -148.96% |
| 2021-12-31 | $83.94 Million | $-53.72 Million | -0.640x | -18.09% |
| 2020-12-31 | $139.83 Million | $-75.78 Million | -0.542x | +50.44% |
| 2019-12-31 | $60.08 Million | $-65.69 Million | -1.093x | -129.01% |
| 2018-12-31 | $67.43 Million | $-32.19 Million | -0.477x | +2.36% |
| 2017-12-31 | $50.34 Million | $-24.61 Million | -0.489x | -63.43% |
| 2016-12-31 | $62.97 Million | $-18.84 Million | -0.299x | +1.63% |
| 2015-12-31 | $36.10 Million | $-10.98 Million | -0.304x | +92.24% |
| 2014-12-31 | $1.87 Million | $-7.33 Million | -3.918x | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a huma… Read more